@prefix this: <http://www.tkuhn.ch/bel2nanopub/RAff4Ybq5nQWnuLWFFRorFWPsPcMwnDQnmCwqH2LIDxAY> .
@prefix sub: <http://www.tkuhn.ch/bel2nanopub/RAff4Ybq5nQWnuLWFFRorFWPsPcMwnDQnmCwqH2LIDxAY#> .
@prefix beldoc: <http://resource.belframework.org/belframework/20131211/knowledge/large_corpus.bel> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix dce: <http://purl.org/dc/elements/1.1/> .
@prefix pav: <http://purl.org/pav/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix belv: <http://www.selventa.com/vocabulary/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix schem: <http://resource.belframework.org/belframework/20131211/namespace/selventa-legacy-chemicals/> .
@prefix hgnc: <http://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=> .
@prefix proteinModification: <http://www.ebi.ac.uk/ontology-lookup/?termId=MOD:00000> .
@prefix psimod: <http://www.ebi.ac.uk/ontology-lookup/?termId=MOD:> .
@prefix obo: <http://purl.obolibrary.org/obo/> .
@prefix occursIn: <http://purl.obolibrary.org/obo/BFO_0000066> .
@prefix do: <http://disease-ontology.org/term/DOID:> .
@prefix species: <http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=> .
@prefix pubmed: <http://www.ncbi.nlm.nih.gov/pubmed/> .
@prefix orcid: <http://orcid.org/> .

sub:Head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo;
    a np:Nanopublication .
}

sub:assertion {
  sub:_1 belv:variantOf hgnc:6877;
    a proteinModification:, psimod:00696 .
  
  sub:_2 occursIn: do:1324, obo:CLO_0007986, species:9606;
    rdf:object sub:_1;
    rdf:predicate belv:decreases;
    rdf:subject schem:Colforsin;
    a rdf:Statement .
  
  sub:assertion rdfs:label "a(SCHEM:Colforsin) -| p(HGNC:MAPK3,pmod(P,T,202))" .
}

sub:provenance {
  beldoc: dce:description "Approximately 61,000 statements.";
    dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved.";
    dce:title "BEL Framework Large Corpus Document";
    pav:authoredBy sub:_4;
    pav:version "20131211" .
  
  sub:_3 prov:value "FSK, an adenylate cyclase activator, also induced strong inhibition of ERK phosphorylation in these cells (Figure 5D). PKA inhibitor, H89, and adenylate cyclase inhibitor, SQ22536, reversed the effect of PGE2-induced inhibition of ERK activation (Figure 5E).";
    prov:wasQuotedFrom pubmed:19570744 .
  
  sub:_4 rdfs:label "Selventa" .
  
  sub:assertion prov:hadPrimarySource pubmed:19570744;
    prov:wasDerivedFrom beldoc:, sub:_3 .
}

sub:pubinfo {
  this: dct:created "2014-07-03T14:33:34.909+02:00"^^xsd:dateTime;
    pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 .
}